Clobetasol pretreatment to reduce and prevent injection site dermatitis from biologic agents

Although anti–tumor necrosis factor and other biologic agents have shown success in controlling distressing dermatologic conditions, such as psoriasis and hidradenitis suppurativa, 12%-37% of patients have injection site reactions that can decrease effectiveness and adherence to therapy. 1 Kaushik S.B. Lebwohl M.G. CME part I psoriasis: which therapy for which patient psoriasis comorbidities and preferred systemic agents. J Am Acad Dermatol. 2019; 80: 27-40 Abstract Full Text Full Text PDF PubMed Scopus (217) Google Scholar , 2 Sorenson E. Koo J. Evidence-based adverse effects of biologic agents in the treatment of moderate-to-severe psoriasis: providing clarity to an opaque topic. J Dermatolog Treat. 2015; 26: 493-501 Google Scholar , 3 Warren R.B. Smith C.H. Yiu Z.Z. et al. Differential drug survival of biologic therapies for the treatment of psoriasis: a prospective observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). J Invest Dermatol. 2015; 135: 2632-2640 Abstract Full Text Full Text PDF PubMed Scopus (289) Google Scholar